Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received a consensus rating of “Moderate Buy” from the twenty-eight ratings firms that are presently covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $95.9565.

A number of analysts have commented on EW shares. Citigroup reiterated a “buy” rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Barclays reaffirmed an “overweight” rating and issued a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Evercore reiterated an “outperform” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Monday, January 5th.

Insider Activity

In related news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,704,682.56. This represents a 51.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 84,398 shares of company stock valued at $7,054,310 over the last three months. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of the stock. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $27,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $25,000. Hilton Head Capital Partners LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at about $28,000. Finally, Kohmann Bosshard Financial Services LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at about $28,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 0.2%

NYSE:EW opened at $80.85 on Friday. Edwards Lifesciences has a twelve month low of $65.94 and a twelve month high of $87.89. The firm has a market capitalization of $46.61 billion, a price-to-earnings ratio of 44.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.95. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average price is $81.65 and its two-hundred day moving average price is $81.75.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same period in the previous year, the company posted $0.59 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts expect that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.